Tritchler, David
https://orcid.org/0000-0002-3177-9657
Mayo Clinic
3GOG Statistical and Data Center, Buffalo, New York
Citations 4
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Secord, Angeles Alvarez , Burdett, Kirsten B. , Owzar, Kouros , Tritchler, David , Sibley, Alexander B. , Starr, Mark D. , Brady, John C. , Lankes, Heather A. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , O’Malley, David M. , Gray, Heidi J. , Boente, Matthew, Burger, Robert A. , Birrer, Michael J. , Bell Burdett, Kirsten , Hurwitz, Herbert I , Fujiwara, Keiichi , O'Malley, David M , Liu, Yingmiao , Bakkum‐Gamez, Jamie N. , Deng, Wei, Nixon, Andrew B.
Clinical Cancer Research | January 9, 2020 | Volume: 26 | Issue: 6 | Pages: 1288-1296
Abstract Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses. Experimental Design: Plasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell–derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates. Results: Baseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (P = 0.007) and OS (P = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (P < 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo. Conclusions: The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.
Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex
Clay‐Gilmour, Alyssa , Hahn, Theresa , Preus, Leah, Onel, Kenan , Skol, Andrew D. , Hungate, Eric A., Zhu, Qianqian , Haiman, Christopher A. , Pooler, Loreall , Sheng, Xin , Yan, Li , Liu, Qian , Liu, Song , Battaglia, Sebastiano , Zhu, Xiaochun , Block, AnneMarie W., Sait, Sheila N.J., Karaesmen, Ezgi , Rizvi, Abbas, Weisdorf, Daniel J. , Tritchler, David , Ellinghaus, Eva , Ellinghaus, David , Stanulla, Martin , Clavel, Jacqueline , Orsi, Laurent , Pasquini, Marcelo C. , Sucheston‐Campbell, Lara E. , Clay-Gilmour, Alyssa I, Ellinghaus, David , Weisdorf, Dan , Clavel, Jacqueline , Stram, Daniel O. , Hu, Qiang , Ambrosone, Christine B. , Spellman, Stephen R. , McCarthy, Philip L.
Blood Advances | October 10, 2019 | Volume: 1 | Issue: 20 | Pages: 1717-1728
10.1182/bloodadvances.2017006023
Key PointsIKZF1 associations with high-risk B-ALL may differ by age and sex. A novel variant on chromosome 14, rs189434316, is associated with over a 3.5-fold risk of normal cytogenetic B-ALL.
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
Tritchler, David , Starr, Mark D. , Brady, John C. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , Gray, Heidi J. , Boente, Matthew, Deng, Wei , Burger, Robert A. , Birrer, Michael J. , Secord, Angeles Alvarez , Liu, Yingmiao , Lankes, Heather A. , O’Malley, David M. , Bakkum‐Gamez, Jamie N. , Fujiwara, Keiichi , Deng, Wei, Nixon, Andrew B.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5521-5521
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant
Karaesmen, Ezgi , Rizvi, Abbas, Preus, Leah, Pasquini, Marcelo C. , Onel, Kenan , Zhu, Xiaochun , Haiman, Christopher A. , Pooler, Loreall , Sheng, Xin , Zhu, Qianqian , Yan, Li , Brock, Guy , Clay‐Gilmour, Alyssa , Battaglia, Sebastiano , Tritchler, David , Liu, Song , Hahn, Theresa , Sucheston‐Campbell, Lara E. , Clay-Gilmour, Alyssa I, McCarthy, Philip L. , Spellman, Stephen R. , Stram, Daniel O. , Liu, Qian , Hu, Qiang , Webb, Amy , Brock, Guy
Blood | August 16, 2017 | Volume: 130 | Issue: 13 | Pages: 1585-1596
Key PointsCandidate SNP associations with survival outcomes after URD transplant are most likely false-positive findings. Over 85% of candidate SNPs are not linked to a biochemical function; of those that are, about half are not linked to the candidate gene.